Compounds > nxl 104
Page last updated: 2024-11-13

nxl 104

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

avibactam sodium : An organic sodium salt that is the monosodium salt of avibactam. Used in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24944097
CHEMBL ID2107817
CHEBI ID85982
SCHEMBL ID14247700
MeSH IDM0539101

Synonyms (54)

Synonym
ave-1330a
avibactam sodium
nxl-104
ave-1330
nxl 104
avibactam sodium [usan]
sulfuric acid, mono((1r,2s,5r)-2-(aminocarbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester, sodium salt (1:1)
1192491-61-4
unii-9v824p8tai
9v824p8tai ,
chebi:85982 ,
avibactam sodium salt
CHEMBL2107817
790235-32-4
avibactam sodium, (+/-)-
sulfuric acid, mono((1r,2s,5r)-2-(aminocarbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester, sodium salt (1:1), rel-
396731-20-7
unii-c8sm6irw7g
1,6-diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt, (1r,2s,5r)-rel-
c8sm6irw7g ,
N-9895
nxl 104, antibiotic for culture media use only
sulfuric acid mono[(1r,2s,5r)-2-(aminocarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl] ester sodium salt
RTCIKUMODPANKX-JBUOLDKXSA-M
SCHEMBL14247700
sodium (1r,2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate
sodium ({[(2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl]oxy}sulfonyl)oxidanide
HY-14879A
AC-29295
avibactam (sodium)
avibactam sodium [who-dd]
1383922-24-4
avibactam sodium salt [mi]
avibactam sodium component of avycaz
avycaz component avibactam sodium
avibactam sodium [jan]
avibactam sodium [orange book]
bdbm159600
us9035062, 23
AKOS030243377
AS-74970
Q27158832
mfcd28900719
sodium (2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate
avibactam sodium; nxl-104
EX-A2293
CCG-267346
sodium;[(2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] sulfate
ave-1330a sodium
A892614
(2s,5r)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide monosodium salt;avibactam sodium
bdbm50512951
DTXSID701027694
sodium(1r,2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-ylsulfate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 3.5.2.6 (beta-lactamase) inhibitorAn EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitor that interferes with the action of beta-lactamase (EC 3.5.2.6).
antibacterial drugA drug used to treat or prevent bacterial infections.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12IC50 (µMol)0.59000.59000.59000.5900AID1553999
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
regulation of cell shapePeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
peptidoglycan biosynthetic processPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
response to antibioticPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
cell wall organizationPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
proteolysisPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
regulation of cell shapePeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
peptidoglycan biosynthetic processPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
cell wall organizationPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
carboxypeptidase activityPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
protein bindingPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
penicillin bindingPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
serine-type D-Ala-D-Ala carboxypeptidase activityPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
peptidoglycan L,D-transpeptidase activityPeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membranePeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
membranePeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
outer membrane-bounded periplasmic spacePeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
plasma membranePeptidoglycan D,D-transpeptidase MrdAEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID1548240Antibacterial activity against Escherichia coli Top10 harboring OXA-48 assessed as ertapenem MIC by CLSI protocol based method (Rvb = 8 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808832Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 53/22-113 (ST-244) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1548226Inhibition of TEM1 (unknown origin) expressed in Escherichia coli BL21 DE3 assessed as K2/Ki ratio using nitrocefin as substrate by spectrophotometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1529350Inhibition of beta lactamase CTX-M-15 in KPC/NDM1 deficient Enterobacteriaceae assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC by broth microdilution method2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1548232Inhibition of Enterobacter cloacae CTX-M-15 expressed in Escherichia coli BL21 DE3 assessed as K2/Ki ratio using nitrocefin as substrate by spectrophotometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808852Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 PAHUAC-27(ST-22) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1529345Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of imipenem-induced antibacterial activity by measuring ceftazidime MIC at 4 ug/ml (Rvb = 16 ug/ml)2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1554005Antibacterial activity against Escherichia coli clinical isolates measured after 16 to 20 hrs by broth microdilution method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID1808823Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaC+pUCP-(PDC-1) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1808826Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaC+pUCP-(PDC-5) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1808875Inhibition beta lactamase PDC-1 in Pseudomonas aeruginosa PAO1 assessed as deacylation off-rate using nitrocefin as substrate at 30 mins measured by 96 well microtitre plate
AID1561472Antibacterial activity against wild type Escherichia coli TG1 in Mueller-Hinton broth by CLSI protocol based method
AID1808877Inhibition beta lactamase PDC-1 in Pseudomonas aeruginosa PAO1 assessed half life of nitrocefin substrate measured by 96 well microtitre plate assay
AID1808811Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaDdeltsDh2deltaDh3 assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1561471Antibacterial activity against wild type beta-lactam-resistant Klebsiella pneumoniae in Mueller-Hinton broth by CLSI protocol based method
AID1808839Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 23/14-053 (ST-309) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1808873Inhibition beta lactamase PDC-1 in Pseudomonas aeruginosa PAO1 using nitrocefin as substrate measured by 96 well microtitre plate
AID1529349Inhibition of beta lactamase CMY-2 in CTX-M-15/CTX-M-14/KPC/NDM1 deficient Enterobacteriaceae assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC by broth microdilution method2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1808841Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 36/14-210 (ST-235) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1808872Inhibition beta lactamase PDC-1 in Pseudomonas aeruginosa PAO1 assessed as inactivation efficiency by measuring acylation rate (k2/K) using nitrocefin as substrate measured by 96 well microtitre plate
AID1553999Inhibition of bocillin-FL binding to Escherichia coli K12 NusA-fused/His6-tagged PBP2 (57 to 615 residues) expressed in Escherichia coli BL21(DE3) preincubated for 30 mins followed by bocillin-FL addition by RT-fluorescence anisotropy method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID1548231Antibacterial activity against Escherichia coli Top10 harboring KPC-2 assessed as aztreonam MIC by CLSI protocol based method (Rvb = 2048 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808817Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaampD assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1548228Antibacterial activity against Escherichia coli Top10 harboring TEM1 assessed as cefamandole MIC by CLSI protocol based method (Rvb = 2048 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808846Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 6/04-224 (ST-175) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1561463Inhibition of OXA-23 in carbapenem-resistant Acinetobacter baumannii ATCC 17978 transfected with pET-RA-KmR plasmid encoding rifampicin and kanamycin resistance assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC
AID1808831Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 36/14-210 (ST-235) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1529343Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC at 4 ug/ml (Rvb = 64 ug/ml)2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1561470Antibacterial activity against wild type carbapenem-susceptible Acinetobacter baumannii ATCC 17978 in Mueller-Hinton broth by CLSI protocol based method
AID1554006Antibacterial activity against Pseudomonas aeruginosa clinical isolates measured after 16 to 20 hrs by broth microdilution method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID1808802Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltadacBdeltaampD assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1604433Inhibition of Pseudomonas aeruginosa KPC-2 assessed as potentiation of piperacillin-induced antibacterial activity at 4 ug/ml by CLSI based broth microdilution method (Rvb = > 64 ug/ml)2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs.
AID1548234Antibacterial activity against Escherichia coli Top10 harboring CTX-M-15 assessed as amoxicillin MIC by CLSI protocol based method (Rvb = 2048 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808809Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltadacBdeltapbpGdeltadacC assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1604434Inhibition of Pseudomonas aeruginosa AmpC assessed as potentiation of piperacillin-induced antibacterial activity at 4 ug/ml by CLSI based broth microdilution method (Rvb = > 64 ug/ml)2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs.
AID1808828Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaC+pUCP-(PDC-5) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1808799Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltadacB assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1808814Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1808851Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 PAHUAC-27(ST-22) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1808805Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltadacBdeltadacC assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1548237Antibacterial activity against Escherichia coli Top10 harboring AmpC assessed as cefotaxime MIC by CLSI protocol based method (Rvb = 256 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808829Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 23/14-053 (ST-309) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1808843Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 53/22-113 (ST-244) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1548241Inhibition of bacterial KPC-2 N132G mutant expressed in Escherichia coli BL21 DE3 assessed as K2/Ki ratio using nitrocefin as substrate by spectrophotometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1554004Antibacterial activity against Pseudomonas aeruginosa UFR49 measured after 16 to 20 hrs by broth microdilution method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID1808800Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltadacB assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1808849Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 PAHUAC-14 (ST-966) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1529347Inhibition of beta lactamase CTX-M-14 in CTX-M-15 deficient Enterobacteriaceae assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC by broth microdilution method2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1548233Antibacterial activity against Escherichia coli Top10 without harboring CTX-M-15 assessed as amoxicillin MIC by CLSI protocol based method (Rvb = 8 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808845Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 6/04-224 (ST-175) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1471280Inhibition of Escherichia coli PBP22017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1548236Antibacterial activity against Escherichia coli Top10 without harboring AmpC assessed as cefotaxime MIC by CLSI protocol based method (Rvb = 0.125 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808815Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1808834Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 13/09-018 (ST-175) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1808836Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 17/14-017 (ST-235) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1471281Antibacterial activity against ESBL/KPC-producing Enterobacter assessed as potentiation of aztreonam induced-antimicrobial activity by measuring aztreonam MIC (Rvb > 16 ug/ml)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1548229Inhibition of KPC-2 (unknown origin) expressed in Escherichia coli BL21 DE3 assessed as K2/Ki ratio using nitrocefin as substrate by spectrophotometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808808Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltadacBdeltapbpGdeltadacC assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1529346Inhibition of beta lactamase KPC in Enterobacteriaceae assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC by broth microdilution method2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1808848Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 PAHUAC-14 (ST-966) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1548235Inhibition of Enterobacter cloacae AmpC expressed in Escherichia coli BL21 DE3 assessed as K2/Ki ratio using nitrocefin as substrate by spectrophotometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808818Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaampD assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1808825Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaC+pUCP-(PDC-1) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1554003Antibacterial activity against Escherichia coli UFR39 measured after 16 to 20 hrs by broth microdilution method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID1808812Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaDdeltsDh2deltaDh3 assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1529348Inhibition of beta lactamase SHV in Enterobacteriaceae assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC by broth microdilution method2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1808821Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaC assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1808803Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltadacBdeltaampD assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1548242Inhibition of Enterobacter cloacae CTX-M-15 N132G mutant expressed in Escherichia coli BL21 DE3 assessed as K2/Ki ratio using nitrocefin as substrate by spectrophotometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808806Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltadacBdeltadacC assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1548230Antibacterial activity against Escherichia coli Top10 without harboring KPC-2 assessed as aztreonam MIC by CLSI protocol based method (Rvb = 0.5 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808871Inhibition beta lactamase PDC-1 in Pseudomonas aeruginosa PAO1 assessed as apparent inhibition constant using nitrocefin as substrate measured by 96 well microtitre plate
AID1548238Inhibition of OXA-48 expressed in Escherichia coli BL21 DE3 assessed as K2/Ki ratio using CENTA as substrate by spectrophotometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1604435Inhibition of Pseudomonas aeruginosa OXA-24/40 assessed as potentiation of piperacillin-induced antibacterial activity at 4 ug/ml by CLSI based broth microdilution method (Rvb = > 64 ug/ml)2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs.
AID1808833Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 13/09-018 (ST-175) assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
AID1548227Antibacterial activity against Escherichia coli Top10 assessed as cefamandole MIC by CLSI protocol based method (Rvb = 2 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1808837Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 17/14-017 (ST-235) assessed as MIC for cefpodoxime antibacterial activity at 4 mg/L by broth microdilution method
AID1548239Antibacterial activity against Escherichia coli Top10 without harboring OXA-48 assessed as ertapenem MIC by CLSI protocol based method (Rvb = < 0.03 ug/ml)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
AID1561464Inhibition of OXA-24/40 in carbapenem-resistant Acinetobacter baumannii ATCC 17978 transfected with pET-RA-KmR plasmid encoding rifampicin and kanamycin resistance assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem M
AID1808820Inhibition of beta-lactamase activity in Pseudomonas aeruginosa PAO1 deltaC assessed as MIC for cefpodoxime antibacterial activity at 16 mg/L by broth microdilution method
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (42.86)24.3611
2020's4 (57.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.80 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		2.1510alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		3.3510penicillin allergen;
penicillin		antibacterial drug
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		3.2710beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
tazobactam
Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.		4.4930penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
pyrrolomycin d
pyrrolomycin D: from Streptomyces strain SF-2080; structure given in first source		2.1510
aspergillomarasmine a
[no description available]		3.3510
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.2110alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
phenylalanine arginine beta-naphthylamide
phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source		2.1510peptide
1-(1-naphthylmethyl)piperazine
[no description available]		2.1510
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.1510capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		3.3510cephalosporin;
oxime O-ether		antibacterial drug
ceftazidime
[no description available]		2.2110cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
mk-7655
relebactam: structure in first source		3.2710
rpx7009
RPX7009: a beta-lactamase inhibitor; structure in first source		3.6620
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Pseudomonas
[description not available]		02.1510
Cronobacter Infections
[description not available]		02.1510
Enterobacteriaceae Infections
Infections with bacteria of the family ENTEROBACTERIACEAE.		02.1510
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.1510
Bacterial Disease
[description not available]		03.1710
Bacterial Infections
Infections by bacteria, general or unspecified.		03.1710